LIVERSTAt™  is a blood-based test utilizing 7 biomarkers from patient’s blood draw and their anthropometrics to generate a quantitative fibrosis assessment and to determine the presence of steatosis only in those subjects without fibrosis.

It is the first line clinical aid for fibrosis/steatosis risk assessment in metabolic subjects..

LIVERSTAt™  is a non-invasive diagnostic and screening tool for liver injury in common liver diseases: Hepatitis C, Hepatitis B, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Alcoholic Liver Disease (ALD).